Pfizer has been granted a patent for pyridine derivatives that are substituted by heterocycle and amino groups. These compounds are antifungal agents and can be used for the treatment of fungal diseases and infections. The patent covers a specific compound with a defined chemical formula. GlobalData’s report on Pfizer gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Pfizer Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Pfizer, Cancer treatment biomarkers was a key innovation area identified from patents. Pfizer's grant share as of September 2023 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11771688B2) discloses a compound and its pharmaceutical applications in the treatment of fungal diseases or infections. The compound, represented by formula (Ib), or its pharmaceutically acceptable derivatives, is claimed to have therapeutic potential.

The compound described in claim 1 of the patent has the formula (Ib) and includes its pharmaceutically acceptable salts, solvates, tautomers, or stereoisomers. In claim 2, it is specified that when W is N+—R15, the compound exhibits certain properties. The nature of R15 is not explicitly mentioned in the claims.

Claim 4 states that when W is N, the compound possesses specific characteristics. Additionally, claim 5 highlights that when X2 is —O— and R13C is substituted or unsubstituted phenyl, the compound demonstrates particular attributes.

The compound's versatility is further emphasized in claim 7, which states that R13C can be hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroalkyl. Claim 9 introduces structural Formula (Ibb) as another representation of the compound.

The patent also covers the use of the compound in pharmaceutical compositions for the treatment of fungal diseases or infections. Claim 10 specifies that the pharmaceutical composition comprises the compound of claim 1 and at least one pharmaceutically acceptable carrier.

Furthermore, claim 11 discloses a method of treating a subject with a fungal disease or infection by administering a therapeutically effective amount of the compound described in claim 1. The fungal diseases or infections mentioned in claim 12 include those caused by Cryptococcus, Aspergillus, Candida, Fusarium, Scedosporium fungi, or fungi from the Mucorales order.

Claim 13 highlights that the method is applicable to fungal diseases or infections that are resistant to azole and/or echinocandin treatments. Finally, claim 14 suggests the administration of at least one additional antifungal agent in combination with the compound of claim 1 as a potential treatment approach.

In conclusion, the granted patent (Publication Number: US11771688B2) discloses a compound and its pharmaceutical applications in the treatment of fungal diseases or infections. The compound, represented by formula (Ib), or its derivatives, shows potential as a therapeutic agent. The patent also covers the use of the compound in pharmaceutical compositions and combination therapies for the treatment of various fungal diseases or infections.

To know more about GlobalData’s detailed insights on Pfizer, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies